[1] Jemal A, Siegel R, Ward E, et al.Cancer statistics[J]. CA Cancer J Clin, 2009, 59(4): 225-249. [2] Nagai H, Sumino Y.Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy[J]. Recent Pat Anticancer Drug Discov, 2008, 3(3): 220-226. [3] Musso M, Scalone R, Bonanno V, et al.Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy[J]. Support Care Cancer, 2009, 17(2): 205-209. [4] Qian YH, Xiao Q, Chen H, et al.Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway[J]. Biochim Biophys Acta, 2009, 1793(5): 764-771. [5] Chipuk JE, Moldoveanu T, Llambi F, et al.The BCL-2 family reunion[J]. Mol Cell, 2010, 37(3): 299-310. [6] Patel MP, Masood A, Patel PS, et al.Targeting the Bcl-2[J]. Curr Opin Oncol, 2009, 21(6): 516-523. [7] Gao CN, Suchida T.Activation of caspases in p53-induced transactivation-independent apoptosis[J]. Jpn J Cancer Res, 1999, 90(2): 180-187. [8] Satoh K, Kaneko K, Hirota M, et al.The pattern of CPP32/caspase-3 expression reflects the biological behavior of the human pancreatic duct cell tumors[J]. Pancreas, 2000, 21(4): 352-357. [9] Fuertes MA, Alonso C, Pérez JM.Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance[J]. Chem Rev, 2003, 103(3):645-662. [10] Anai S, Sakamoto N, Sakai Y, et al.Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer[J]. Urol Oncol, 2011, 29(4): 421-429. [11] Han D, Denison MS, Tachibana H, et al.Effects of estrogenic compounds on immunoglobulin production by mouse splenocytes[J]. Biol Pharm Bull, 2002, 25(10): 1263-1267. |